Cognition Therapeutics, Inc. (CGTX)
CGTX moved a median of -1.11% 30 minutes after news, and -1.11% by the close. How CGTX actually reacts to news — the realized, point-in-time move the market made, measured across 224 labeled events over the last three years with zero look-ahead.
CGTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 221 |
| 30-min | -1.11% | 39% | 224 |
| 60-min | -0.43% | 45% | 224 |
| to close | -1.11% | 39% | 222 |
| Middle 50% of CGTX reactions | -3.71% to +1.95% |
|---|---|
| Median reaction (30-min) | -1.11% |
| Measured reactions | 224 |
Half of all Cognition Therapeutics, Inc. news events land between -3.71% and +1.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CGTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CGTX's baseline. Nothing else.
Recent CGTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 | Press release | GlobeNewswire | -0.56% | -11.42% | |
| Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB | Press release | GlobeNewswire | +0.45% | -0.58% | |
| Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference | Press release | GlobeNewswire | -1.47% | -0.98% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.82% | -1.82% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | Press release | GlobeNewswire | +1.82% | -1.82% | |
| Form 8-K COGNITION THERAPEUTICS For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.82% | -1.82% | |
| Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit | Press release | GlobeNewswire | -2.86% | -2.86% | |
| Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | Press release | GlobeNewswire | -13.84% | -35.85% | |
| Form 8-K COGNITION THERAPEUTICS For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -13.84% | -35.85% | |
| Form 8-K COGNITION THERAPEUTICS For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | -2.03% | |
| Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 | Press release | GlobeNewswire | -1.62% | +3.28% | |
| Form 8-K COGNITION THERAPEUTICS For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +8.82% | +0.00% | |
| Cognition Therapeutics Participating in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.42% | +6.84% | |
| Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis | Press release | GlobeNewswire | +0.00% | -0.79% | |
| Form 8-K COGNITION THERAPEUTICS For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.79% | |
| Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | Press release | GlobeNewswire | -4.11% | -1.64% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.43% | +3.42% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | Press release | GlobeNewswire | -0.43% | +3.42% | |
| Form 8-K COGNITION THERAPEUTICS For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +3.42% | |
| Form ARS COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.01% | +1.59% | |
| Form DEF 14A COGNITION THERAPEUTICS For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +0.01% | +1.59% | |
| Form DEFA14A COGNITION THERAPEUTICS | SEC filing · Form DEFA14A | SEC EDGAR | +0.01% | +1.59% | |
| Cognition Therapeutics to Present at Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.31% | +6.49% | |
| Cognition Therapeutics CEO Issues Letter to Shareholders | Press release | GlobeNewswire | +2.51% | +11.43% | |
| Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update | Press release | GlobeNewswire | -1.79% | -3.57% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.79% | -3.57% | |
| Form 8-K COGNITION THERAPEUTICS For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -3.57% | |
| Form S-8 COGNITION THERAPEUTICS | SEC filing · Form S-8 | SEC EDGAR | -1.79% | -3.57% | |
| Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results | Press release | GlobeNewswire | +0.93% | +4.63% | |
| Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 | Press release | GlobeNewswire | +1.83% | +4.54% | |
| Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis | Press release | GlobeNewswire | +1.40% | -0.94% | |
| Form 8-K COGNITION THERAPEUTICS For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | -0.94% | |
| Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | Press release | GlobeNewswire | +1.44% | -3.88% | |
| Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies | Press release | GlobeNewswire | -2.14% | -5.71% | |
| Form 8-K COGNITION THERAPEUTICS For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | -5.71% | |
| Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies | Press release | GlobeNewswire | -1.40% | -1.40% | |
| Form EFFECT COGNITION THERAPEUTICS | SEC filing · Form EFFECT | SEC EDGAR | -0.69% | -2.08% | |
| Form 8-K COGNITION THERAPEUTICS For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | +2.67% | |
| Form S-3 COGNITION THERAPEUTICS | SEC filing · Form S-3 | SEC EDGAR | -1.67% | +2.67% | |
| Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | Press release | GlobeNewswire | +1.23% | +10.43% | |
| Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference | Press release | GlobeNewswire | -4.74% | -8.00% | |
| Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference | Press release | GlobeNewswire | +0.00% | +2.21% | |
| Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease | Press release | GlobeNewswire | -2.71% | — | |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs | Press release | GlobeNewswire | +0.00% | -1.19% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.19% | |
| Form 8-K COGNITION THERAPEUTICS For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.19% | |
| Form 8-K COGNITION THERAPEUTICS For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -30.94% | |
| Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target | Press release | GlobeNewswire | -2.88% | -2.47% | |
| Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) | Press release | GlobeNewswire | -2.88% | -2.47% | |
| Form 8-K COGNITION THERAPEUTICS For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -1.37% | -4.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CGTX section they belong to.
Where else CGTX is measured.
CGTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cognition Therapeutics, Inc.'s median reaction calculated?
Every labeled CGTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 224 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of CGTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CGTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.